Avoro Capital Advisors
NEW YORK, NYfiles as Avoro Capital Advisors LLC
$11.1bn in 26 US stocks at the end of 30 June 2026. The top 10 are 79.5% of the money. It changed about 28.3% of the portfolio this quarter.
Value
$11.1bn
Stocks
26
Top 10 share
79.5%
Turnover
28.3%
What changed this quarter
New
Bought for the first time this quarter.
- Ascendis Pharma A/SASND12.2% of the fund
- Hemab Therapeutics HoldingsCOAG0.6% of the fund
- Faeth TherapeuticsFTH0.3% of the fund
Added
Bought more of a stock they already held.
- United TherapeuticsUTHR13.5% of the fund+6%
- Arrowhead PharmaceuticalsARWR8.3% of the fund+6%
- CytokineticsCYTK3.8% of the fund+50%
- Definium TherapeuticsDFTX3.0% of the fund+44%
- uniQureQURE2.8% of the fund+13%
- Taysha Gene TherapiesTSHA1.5% of the fund+10%
- Viridian TherapeuticsVRDN0.4% of the fund+67%
- Avalo TherapeuticsAVTX0.4% of the fund+65%
Cut
Sold some of their stake.
- Revolution MedicinesRVMD3.9% of the fund-2%
- Vera TherapeuticsVERA2.2% of the fund-3%
- Lexeo TherapeuticsLXEO<0.1% of the fund-21%
Sold out
Sold their entire stake.
- Ascendis Pharma A/SASND-100%
- Apellis Pharmaceuticals-100%
- Centessa Pharmaceuticals-100%
- Terns Pharmaceuticals-100%
- Soleno Therapeutics-100%
- Alkermes plc.ALKS-100%
- MannkindMNKD-100%
Holdings
- Argenx SEARGX
- Share
- 8.3%
- Value
- $928m
- Shares
- 1,000,000
Held
- Structure TherapeuticsGPCR
- Share
- 3.2%
- Value
- $352m
- Shares
- 6,555,555
Held
- Damora Therapeutics
- Share
- 0.9%
- Value
- $98m
- Shares
- 3,783,000
Held
- Hemab Therapeutics HoldingsCOAG
- Share
- 0.6%
- Value
- $71m
- Shares
- 1,925,150
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| United TherapeuticsUTHR | 13.5% | $1.5bn | 2,777,777 | +6% |
| Ascendis Pharma A/SASND | 12.2% | $1.4bn | 5,111,111 | New |
| Krystal BiotechKRYS | 9.6% | $1.1bn | 2,888,888 | Held |
| Madrigal PharmaceuticalsMDGL | 8.8% | $984m | 1,833,333 | Held |
| Argenx SEARGX | 8.3% | $928m | 1,000,000 | Held |
| Arrowhead PharmaceuticalsARWR | 8.3% | $926m | 11,355,555 | +6% |
| Kymera TherapeuticsKYMR | 7.7% | $857m | 7,474,747 | Held |
| Revolution MedicinesRVMD | 3.9% | $430m | 2,297,000 | -2% |
| CytokineticsCYTK | 3.8% | $426m | 4,999,999 | +50% |
| CelcuityCELC | 3.2% | $356m | 3,400,000 | Held |
| Structure TherapeuticsGPCR | 3.2% | $352m | 6,555,555 | Held |
| Xenon PharmaceuticalsXENE | 3.1% | $349m | 5,777,777 | Held |
| Definium TherapeuticsDFTX | 3.0% | $338m | 7,188,888 | +44% |
| uniQureQURE | 2.8% | $310m | 6,727,777 | +13% |
| Vera TherapeuticsVERA | 2.2% | $246m | 5,723,888 | -3% |
| Taysha Gene TherapiesTSHA | 1.5% | $163m | 23,888,888 | +10% |
| Ocular TherapeutixOCUL | 1.1% | $123m | 12,540,000 | Held |
| Damora Therapeutics | 0.9% | $98m | 3,783,000 | Held |
| Hemab Therapeutics HoldingsCOAG | 0.6% | $71m | 1,925,150 | New |
| GH ResearchGHRS | 0.4% | $48m | 1,800,000 | Held |
| Viridian TherapeuticsVRDN | 0.4% | $46m | 2,500,000 | +67% |
| SepternaSEPN | 0.4% | $45m | 1,337,500 | Held |
| Avalo TherapeuticsAVTX | 0.4% | $43m | 2,333,333 | +65% |
| Faeth TherapeuticsFTH | 0.3% | $36m | 1,444,039 | New |
| Whitehawk TherapeuticsWHWK | 0.1% | $13m | 2,849,402 | Held |
| Lexeo TherapeuticsLXEO | <0.1% | $7m | 1,489,189 | -21% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 95.0% since 30 June 2025.
Where the money is
Health care87.6%
Other12.4%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.